{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table A Recommended dose modifications for enfortumab vedotin associated hematologic', 'toxicity*', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Continue at same dose', 'Continue at same dose', 'Withhold dose until', 'Withhold dose until', 'level.', 'level.', 'toxicity is < Grade 1 or has', 'toxicity is VI Grade 1 or has', 'For Grade 2', 'returned to baseline, then', 'returned to baseline, then', 'resume treatment at the', 'thrombocytopenia,', 'reduce dose by 1 dose level', 'withhold', 'same dose level or consider', 'and resume treatment, or', 'dose reduction by 1 dose', 'discontinue at the', 'dose until toxicity is', 'level.', 'discretion of the', '< Grade 1 or has returned', 'to baseline, then resume', 'Transfusions or growth', 'investigator.', 'treatment at the same dose', 'factors may be used as', 'Transfusions or growth', 'level.', 'indicated per institutional', 'factors may be used as', 'guidelines.', 'indicated per institutional', 'guidelines.', 'For anemia, treatment', 'discontinuation should be', 'strongly considered.', '*Note: hematological toxicity refers to anemia, thrombocytopenia, neutropenia and febrile neutropenia.', 'Table B Recommended dose modifications for enfortumab vedotin associated', 'nonhematologic toxicity', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Continue at same dose', 'Continue at same dose', 'Withhold dose until', 'For Grade 4 AEs,', 'level.', 'level, except in the event', 'toxicity is VI Grade 1 or has', 'discontinue treatment.*', 'If ocular symptoms and/or', 'of Grade 2 neuropathy or', 'returned to baseline, then', 'Grade 4 vomiting and/or', 'changes in vision are', 'corneal AEs.', 'resume treatment at the', 'diarrhea that improves to', 'identified, the subject', 'For Grade 2 neuropathy or', 'same dose level or', '< Grade 2 within 72 hours', 'should be evaluated with an', \"corneal AE's, withhold\", 'consider dose reduction by', 'with supportive', 'ophthalmologic exam.**', 'dose until toxicity is', '1 dose level.', 'management does not', '< Grade 1 or has returned', 'For Grade 3 neuropathy or', 'require discontinuation.', 'to baseline, and then', 'corneal AEs, discontinue', 'resume treatment at the', 'treatment', 'same dose level. For the', 'For Grade 3', 'second occurrence of', 'hyperglycemia/elevated', 'Grade 2 neuropathy or', 'blood glucose, withhold', \"corneal AE's withhold\", 'EV treatment. Resume', 'dose until toxicity is VI', 'treatment once', 'Grade 1, and then reduce', 'hyperglycemia/elevated', 'the dose by 1 dose level', 'blood glucose has', 'and resume treatment.', 'improved to < Grade 2 and', 'If ocular symptoms and/or', 'subject is clinically and', 'changes in vision are', 'metabolically stable.', 'identified, the subject', 'If ocular symptoms and/or', 'should be evaluated with an', 'changes in vision are', 'ophthalmologic exam.**', 'identified, the subject', 'should be evaluated with an', 'ophthalmologic exam.**', 'AE: adverse events; EV: enfortumab vedotin', '*', 'Grade 3/4 electrolyte imbalances/laboratory abnormalities that are not associated with clinical sequelae and/or are', 'corrected with supplementation/appropriat management within 72 hours of their onset do not require discontinuation', '(e.g., Grade 4 hyperuricemia). Grade 3 rash that is not limiting self-care activities of daily living or associated with', 'infection requiring systemic antibiotics does not require treatment interruption, provided symptoms are not severe and', 'can be managed with supportive treatment.', '**Ophthalmologic exam should be performed by an ophthalmologist. In countries where optometrists can perform exams', 'and prescribe medications, an optometrist may be used instead.', '14 Sep 2020', 'Astellas', 'Page 24 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Comparative Drug(s):', 'In general, treatment with the chemotherapy comparators (docetaxel, paclitaxel or vinflunine)', 'should be withheld for drug related Grade 4 hematologic toxicities and for non-hematologic', 'toxicities Grade 3, and subsequent doses modified as per Table 6 Recommended dose', 'modification guidelines specific for subjects receiving docetaxel, paclitaxel or vinflunine are', 'detailed below. Dose modifications should also be considered according to local product labels or', 'summary of product characteristics (SmPC) and institutional guidelines. For docetaxel, paclitaxel', 'or vinflunine associated hematologic toxicities > Grade 3, transfusions or growth factors may be', 'used as indicated per institutional guidelines.', 'Docetaxel', 'Dose, Mode of Administration and Dose Modification:', 'Docetaxel will be administered intravenously on Day 1 of every 21-day cycle. The starting dose of', 'docetaxel 75 mg/m\u00b2 will be administered over 60-minute period or per local requirement. Refer to', 'local product label or SmPC and institution guidelines for docetaxel for further guidance on', 'docetaxel dosing.', 'Docetaxel should not be given to subjects with total bilirubin > ULN, or to subjects with AST', 'and/or ALT > 1.5 X ULN with concomitant alkaline phosphatase > 2.5 X ULN. Subjects with', 'elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at', 'increased risk for the development of Grade 4 neutropenia, febrile neutropenia, infections, severe', 'thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Docetaxel should also', 'not be given to subjects with a neutrophil count of < 1500 cells/mm\u00b3 Severe fluid retention has', 'been reported following docetaxel therapy.', 'Subjects should be premedicated with corticosteroids per institutional guidelines prior to each', 'docetaxel administration. Subjects with pre-existing effusions should be closely monitored from', 'the first dose for the possible exacerbation of the effusions. Subjects developing peripheral edema', 'may be treated with standard measures, e.g., salt restriction, oral diuretic(s) Dose interruptions', 'may last up to 6 weeks (2 cycles). Dose interruptions for subjects who are deriving clinical benefit', \"from treatment may be extended beyond 6 weeks, if the subject's toxicity does not otherwise\", 'require permanent discontinuation.', 'Dose modifications not specified in Table C (e.g., severe or cumulative cutaneous reactions)', 'should also be considered according to local product label or SmPC and institutional guidelines.', 'Table C', 'Recommended dose modifications for subjects receiving docetaxel', 'Toxicity', 'Grade', 'Occurrence', 'Hold Treatment', 'Dose Modification', 'Discontinue', 'Treatment', 'Peripheral', 'Grade 1,', 'No', '60 mg/m\u00b2', 'N/A', 'Neuropathy', '2', 'Grade 3,', 'Yes', 'N/A', 'Discontinue', '4', 'upon onset', 'Neutropenic', '1', 'Hold treatment', '60 mg/m\u00b2', 'fever (defined as', 'until ANC', 'T> 100.5\u00b0F (38.1\u00b0C)', '1,500/L', 'and', '2', 'Hold treatment', '50 mg/m\u00b2', 'ANC VI 1,000/L)', 'until ANC', '> 1,500/L', '3', 'Yes', 'N/A', 'Yes', 'ANC: absolute neutrophil count; N/A: not applicable; T: temperature', '14 Sep 2020', 'Astellas', 'Page 25 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}